These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 29723247)
1. Fc engineering of anti-Nectin-2 antibody improved thrombocytopenic adverse event in monkey. Oshima T; Miyashita H; Ishimura Y; Ito Y; Tanaka Y; Hori A; Kokubo T; Kurokawa T PLoS One; 2018; 13(5):e0196422. PubMed ID: 29723247 [TBL] [Abstract][Full Text] [Related]
2. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers. Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976 [TBL] [Abstract][Full Text] [Related]
3. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ MAbs; 2015; 7(3):494-504. PubMed ID: 25933349 [TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys. Campbell DO; Noda A; Verlinsky A; Snyder J; Fujita Y; Murakami Y; Fushiki H; Miyoshi S; Lacayo S; Cabral E; Yang P; Stover DR; Joseph IB Mol Imaging Biol; 2016 Oct; 18(5):768-75. PubMed ID: 27122234 [TBL] [Abstract][Full Text] [Related]
5. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563 [TBL] [Abstract][Full Text] [Related]
6. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787 [TBL] [Abstract][Full Text] [Related]
7. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029 [TBL] [Abstract][Full Text] [Related]
8. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035 [TBL] [Abstract][Full Text] [Related]
9. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058 [TBL] [Abstract][Full Text] [Related]
10. Modulating antibody-dependent cellular cytotoxicity of epidermal growth factor receptor-specific heavy-chain antibodies through hinge engineering. D'Eall C; Pon RA; Rossotti MA; Krahn N; Spearman M; Callaghan D; van Faassen H; Hussack G; Stetefeld J; Butler M; Durocher Y; Zhang J; Henry KA; Tanha J Immunol Cell Biol; 2019 Jul; 97(6):526-537. PubMed ID: 30680791 [TBL] [Abstract][Full Text] [Related]
11. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody. Zhang D; Goldberg MV; Chiu ML J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634 [TBL] [Abstract][Full Text] [Related]
13. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195 [TBL] [Abstract][Full Text] [Related]
14. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Zalevsky J; Leung IW; Karki S; Chu SY; Zhukovsky EA; Desjarlais JR; Carmichael DF; Lawrence CE Blood; 2009 Apr; 113(16):3735-43. PubMed ID: 19109559 [TBL] [Abstract][Full Text] [Related]
15. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies. Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558 [TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity. Liu W; Yu J; Sun K; Song Q; Li Y; He Y; Wang Y; Xu G; Wang C; Chen B Front Immunol; 2024; 15():1410457. PubMed ID: 38765013 [TBL] [Abstract][Full Text] [Related]
17. A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma. Zheng J; Guo Y; Ji X; Cui L; He W Cancer Lett; 2013 Dec; 341(2):150-8. PubMed ID: 23920126 [TBL] [Abstract][Full Text] [Related]
18. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris. Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261 [TBL] [Abstract][Full Text] [Related]
19. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226 [TBL] [Abstract][Full Text] [Related]
20. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]